A randomized, open label, outcomes-assessor masked, prospective, parallel controlled group, phase 3 clinical trial of retinal gene therapy for choroideremia using an adeno-associated viral vector (AAV2) encoding Rab escort protein 1 (REP1). Here, CHM is linked to choroideremia.